Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:58:48 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:IVBIY from 2023-05-03 to 2024-05-02 - 48 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-07 20:00U:IVBIYNews ReleaseInnovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
2024-04-02 01:00U:IVBIYNews ReleaseInnovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
2024-03-26 20:00U:IVBIYNews ReleaseInnovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
2024-03-20 07:41U:IVBIYNews ReleaseInnovent Announces 2023 Annual Results and Business Updates
2024-03-18 20:00U:IVBIYNews ReleaseInnovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
2024-03-11 20:00U:IVBIYNews ReleaseInnovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
2024-03-06 22:41U:IVBIYNews ReleaseInnovent released the results of two clinical studies of IBI311 (an anti-IGF-1R monoclonal antibody) in oral presentations at the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024
2024-03-05 00:32U:IVBIYNews ReleaseInnovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
2024-02-29 19:00U:IVBIYNews ReleaseInnovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an anti-IL-4Ralpha/TSLP bispecific antibody) in Australia
2024-02-19 19:21U:IVBIYNews ReleaseInnovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
2024-02-07 03:35U:IVBIYNews ReleaseInnovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
2024-02-05 03:41U:IVBIYNews ReleaseInnovent Announces Retirement of CFO and Appointment of New CFO
2024-01-08 19:00U:IVBIYNews ReleaseInnovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
2024-01-01 19:00U:IVBIYNews ReleaseInnovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
2023-12-27 19:00U:IVBIYNews ReleaseInnovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
2023-12-26 19:00U:IVBIYNews ReleaseInnovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
2023-12-18 19:00U:IVBIYNews ReleaseInnovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
2023-12-17 19:00U:IVBIYNews ReleaseInnovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
2023-12-12 23:51U:IVBIYNews ReleaseInnovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT ‚ ® 's Seventh Indication and BYVASDA ‚ ®'s Eighth Indication
2023-12-06 20:00U:IVBIYNews ReleaseInnovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
2023-12-05 19:16U:IVBIYNews ReleaseInnovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
2023-11-30 23:00U:IVBIYNews ReleaseInnovent Presents Clinical Data Update of IBI351 (KRAS G12C Inhibitor) Monotherapy in Lung Cancer and Colorectal Cancer at ESMO Asia Congress 2023
2023-11-30 07:00U:IVBIYNews ReleaseInnovent's MSCI ESG Rating Upgraded to A
2023-11-23 19:38U:IVBIYNews ReleaseChina's First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351
2023-11-22 08:30U:IVBIYNews ReleaseInnovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Accepted the New Drug Application for Taletrectinib (ROS1 Inhibitor)
2023-11-21 23:34U:IVBIYNews ReleaseInnovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
2023-11-05 19:00U:IVBIYNews ReleaseInnovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023
2023-10-29 20:00U:IVBIYNews ReleaseInnovent Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity
2023-10-08 20:00U:IVBIYNews ReleaseInnovent Announces First Patient Dosed in the Phase 3 Clinical Study (STAR) of Efdamrofusp Alfa (IBI302), a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Neovascular Age-related Macular Degeneration
2023-09-28 20:00U:IVBIYNews ReleaseInnovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO ‚ ® (Equecabtagene Autoleucel) at IMS 2023
2023-08-23 07:14U:IVBIYNews ReleaseInnovent Announces 2023 Interim Results and Business Updates
2023-08-16 20:00U:IVBIYNews ReleaseInnovent Announces the NMPA Approval of SINTBILO ‚ ® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia
2023-08-07 22:56U:IVBIYNews ReleaseInnovent Announces the Preclinical Results of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) were Published in Nature Cancer
2023-07-02 20:00U:IVBIYNews ReleaseInnovent and IASO Bio Announce the NMPA Approval of FUCASO ‚ ®, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma
2023-06-25 20:00U:IVBIYNews ReleaseInnovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT ‚ ® (sintilimab injection) and Novel ADC Candidates for Advanced Solid Tumors in China
2023-06-11 20:00U:IVBIYNews ReleaseInnovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting
2023-06-05 20:00U:IVBIYNews ReleaseInnovent Presents Phase 1 Clinical Data of IBI351 (KRASG12C Inhibitor) as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting
2023-06-05 20:00U:IVBIYNews ReleaseInnovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting
2023-06-04 20:00U:IVBIYNews ReleaseInnovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting
2023-06-03 20:00U:IVBIYNews ReleaseInnovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
2023-06-02 19:59U:IVBIYNews ReleaseInnovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
2023-06-01 20:00U:IVBIYNews ReleaseInnovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX ‚ ®)for KRASG12C-mutated NSCLC in China
2023-05-16 20:00U:IVBIYNews ReleaseInnovent Announces Clinical Data of Multiple Trials Will be Presented at the 2023 ASCO and EHA Annual Meetings
2023-05-14 20:00U:IVBIYNews ReleaseInnovent Receives NMPA Breakthrough Designation for IBI351 (KRASG12C Inhibitor) as Monotherapy for Previously Treated Advanced Colorectal Carcinoma
2023-05-10 20:45U:IVBIYNews ReleaseInnovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
2023-05-09 20:00U:IVBIYNews ReleaseThe China NMPA Approves TYVYT ‚ ® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
2023-05-07 20:00U:IVBIYNews ReleaseInnovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
2023-05-07 20:00U:IVBIYNews ReleaseInnovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease